


Inipharm, <https://inipharm.com/>, founded 2018, privately held, HQ: Bellevue, WA, Not currently raising funds, please contact: Brian Farmer, bfarmer@inipharm.com

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's clinical lead program is focused on the highly validated, genetically-defined target, HSD17B13.

Inactive alleles of HSD17B13 are protective against liver disease



*95% CI; ¹ rs72613567 ² rs143404524. Odds Ratios are calculated for homozygous polymorphisms vs. WT, comparing patients with disease to either healthy normal or patients with mild phenotype of disease (depending on study) SOURCES: Gellert-Kristensen 2019; Abul-Husn 2018; Kozlitina 2018; About 2018; Ferenci 2019, Yang 2020 Hepatol; About 2018 NEJM

There is extensive evidence that genetic variants which express inactive HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on novel insights into the biologic activity of HSD17B13, Inipharm identified an orally delivered, small molecule HSD17B13 inhibitor, INI-822. INI-822 is currently in Phase 1 development. INI-822, believed to be the first small molecule inhibitor of HSD17B13 to advance to clinical development, is under development for fibrotic liver diseases, including metabolically associated steatohepatitis (MASH aka NASH).

In preclinical studies, INI-822 was shown to potently and selectively inhibit HSD17B13, and when dosed in animal models, demonstrated improvements in markers of liver homeostasis. These included a reduction in liver transaminases and specific bioactive lipids, and the enrichment of hepatic lipid species that were also identified in patients with the protective variant of HSD17B13.